Smart-Money SignalDistribution · 39/100— Insiders are net sellers over 90 days (-$7.7M, 49 sales vs 14 buys)
Revenue$51.7M
Net Income-$13.3M
EPS$-0.67
Market Cap$6.4B
Price Performance
Historical data including institutional events
Company Profile
T
Todd C. Davis
CEO & Executive Director
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
